3
). Results. A total of 4,660 patients attended at least one visit primary care visit at CORE between March 31, 2017 and April 1, 2018, of whom 84% were virologically suppressed. Sixty-six percent of our patients were African-American (AA), and 25% identified as Hispanic; 74% were male; patients' median age was 49. On multivariate analysis, AA race (OR 1.54, P = 0.006) correlated with ongoing viremia (VL > 200 copies/mL 3 ), while older age (age group 30 -49, OR 0.62, P < 0.001; age group > 50 OR 0.27, P < 0.001) and identification as Hispanic (OR 0.63, P = 0.011) associated with virologic suppression. Other HIV transmission categories and demographic characteristics, inclusive of a health literacy measure, did not associate with virologic control. Of the Top 10 most populated zip codes of residence for our patients, three had a significantly higher proportion of viremic patients; while one had significantly more suppressed patients.
Conclusion. Disparities in virologic suppression persist in younger and AfricanAmerican PLWH who attended care at Chicago's largest, safety-net HIV clinic, with our data highlighting particular geographic areas of need. Structural interventions and quality improvement initiatives, at the health system and regional level, must continue to focus on improving outcomes for PLWH who fall into these demographic categories.
Disclosures. R. Lubelchek, Viiv: Scientific Advisor, Salary. October 4, 2018: 12:30 PM Background. One of the issues faced by clinics which care for young adults infected with HIV is a disruption to treatment during the transition from pediatric to adult care. Adherence to routine treatment is essential for this population to ensure decreased rates of transmission and favorable health outcomes for the patients. The purpose of this study was to characterize the out of care transitioning patient population from pediatric to adult HIV care in an academic HIV clinic in Detroit, Michigan.
Barriers to Transitions of Care in the Detroit
Methods. We assessed barriers to transition for youth with HIV who had not met the requirements for successful transition to the adult HIV clinic (three appointments). Patient barriers were assessed through telephone calls with three questions assessing their reasons for not coming to the adult clinic conducted by adult medical staff and by a pediatric social worker.
Results. One hundred and four youth were identified as transitioning youth. Of those, 13 were excluded due to relocation. Thirty-two (30.7%) patients did not successfully transition and 19 (18%) were accessible through telephone/text for interview. Demographic data for the 32 patients was collected and the predictors of disengagement were identified which included transportation (22.2, n = 10) and work (8.9%, n = 4). There were no statistically significant differences in the measured variables of race, HIV mode of acquisition, housing status, or employment status between those who did and did not successfully transition. In regards to reasons for missed appointments, there were eight reasons given to the adult medical staff, but the pediatric social worker was able to elicit, a much broader range of answers, 13.
Conclusion. We found that lack of phone access, transportation and work play a key role in patients transitioning to the adult clinic; however, we initially expected more socioeconomic factors to impair the transition process. In looking at the mismatched reasons for missed appointments given to the adult clinic and the pediatric social worker, it appears that the pediatric social worker could elicit a greater the variety of reasons for missed appointments. Moving forward, more pediatric social work support for the transitioning process may be beneficial. Background. Engagement-in-care is a key component of the HIV care cascade. The CDC reports an engagement-in-care rate for people living with HIV (PLWH) of only 58%. Given the resource intense nature of care re-engagement efforts, it may be useful to identify sub-groups of lost-to-care (LTC) patients at lower risk for poor outcomes. We report on a group of patients whom have had no medical visit, but whom have had lab monitoring in the last year, and who may not require as intense re-engagement interventions.
Methods. At the Ruth M. Rothstein CORE Center, a large, Chicago-area, safety-net HIV clinic which cares for nearly 5,000 PLHW, between April 1, , 2017 and February 1, 2018 we identified patients who had no medical visit within the prior 12 months, but at least one visit in the prior 36 months. Such LTC patients that had no lab monitoring at outside clinics, as determined via collaboration with Chicago Department of Public Health, are included in our analysis. We defined LTC patients as either "true", if they had no visits or lab monitoring city-wide or "virtual" if they had lab monitoring at the CORE Center, but no medical visits. We report on clinical and demographic differences for these "true" vs. "virtual" LTC patients, and perform logistic regression, assessing for correlation with whether patients subsequently returned to care.
Results. Five hundred patients met our LTC definition; 55 "virtual" and 445 "true. " "Virtual" vs. "true" LTC patients more likely had private insurance (18% vs.
Background. Initiation of combined antiretroviral therapy (cART) has markedly increased survival and quality of life in HIV-infected patients. With the advent of new treatment options, including an increasing number of single-tablets, the durability of first-line ART regimes is developing.
Methods. We used data from the prospective multicenter German Clinical Surveillance of HIV Disease (ClinSurv) cohort of the Robert-Koch-Institute. Time to event was calculated as time between initiation of first-line cART and therapy change. We used a Cox model to assess predictors of treatment change 1 year after starting cART.
Results. We included 6,894 patients who initiated ART between 2005 and 2014. The sample population was predominantly men (79%) with German origin (69.8%), of which 49.6% were reporting sex with men (MSM) as main risk factor. Median age (IQR) was 38 (31-46) years. The most frequently treatment combinations were 2NRTI/PIr (48.1%) and 2NRTI/1NNRTI (42.2%), 2NRTI/1II (5.2%). 22.6% patients changed their first-line treatment within 1 year. Median (IQR) length between first intake and stop of the regime was 105 (35-214) days, which did not change significantly between 2005 (108; 38-217) and 2014 (128; 74-200) (P = 0.28). Most common documented causes were side effects of drugs 418 (44.0%) and non-adherence 173 (18.2%). In the Cox model (Figure 1 ), we identified numerous covariates associated with discontinuation of the first-line regime. A 2NRTI/1NNRTI regime was associated with higher rates (hazard ratio [HR] 1.28, 95% CI 1.06-1.55) and a 2NRTI/1II regime with lower rates (HR 0.34, 95% CI 0.23-0.51) of treatment modification (ref.: 2NRTI/1PIr). The HR increased markedly with the amount of daily-administered tablets from HR 2.15, 95% CI 1.48-3.11 (2-3 tablets) to HR 3.98, 95% CI 2.16-7.31 (10 tablets) (ref.: one tablet). We observed an association with a baseline viral load (VL) of >100 copies/mL (HR 0.65, 95% CI 0.53-0.81) and >100.000 copies/ mL (HR 0.68, 95% CI 0.54-0.85) (ref.: VL > 1 Mio. copies/mL).
Conclusion. Our analysis revealed, that side effects of drugs, the number of tablets per day and the VL at baseline are significantly associated with treatment change within the first year. A first-line regime with 2NRTI/1II seems to improve the adherence to the initial regime significantly.
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No reported disclosures. Background. As HIV antiretroviral therapy (ART) becomes increasingly more simplified and effective, many patients living with HIV benefit with reduced ART pill burden and longer life expectancy. As this patient population ages, the prevalence of comorbidities increases the likelihood of polypharmacy. This study assessed if comorbidities and their associated polypharmacy affect the success of HIV management in our patients.
Do Comorbidities and Polypharmacy Lead to
Methods. A retrospective analysis of patients living with HIV receiving care at an urban clinic in New Jersey was performed. Eligible patients were ≥18 years old, had ≥2 visits in 2017 with laboratory data ≥24 weeks apart. These patients were divided into three arms: those without any comorbid conditions, a single comorbidity, and patients with multiple comorbidities. The primary endpoints were to determine the effect of comorbid conditions and polypharmacy on viral suppression (defined as HIV RNA <20 copies/mL). Secondary assessments accounted for the impact of age and race/ethnicity on HIV management.
Results. There were 318 patients included in the analysis: 156 with multiple comorbidities, 76 with one, and 86 without any. Most patients were male (58%) and the mean age was 49 years old. The population was 52% Black, 32% Hispanic, and 15% White. Most patients (72%) had undetectable virus, and 92% had a CD4 count >200 cells/mm 3 . Patients with multiple comorbidities were more likely to be virologically suppressed than patients with one comorbidity (80% vs. 59%, P = 0.0014) and those without (80% vs. 67%, P = 0.0413), despite having a higher pill burden per day (7.0 vs. 3.7 vs. 2.2, P = 0.0001). Although age was not an independent predictor of viral suppression, patients with multiple comorbidities were older (55 yo) than those with one comorbidity (48 yo) and without any (41 yo) (both P < 0.0001). Hypertension (39%), diabetes mellitus (16%), dyslipidemia (31%), and psychiatric disorders (14%) were the most common comorbidities. Patients with hypertension were more likely to be virologically suppressed than those without (80% vs. 67%, P = 0.0229).
Conclusion. Patients with multiple comorbidities and a greater daily pill burden at our clinic were more likely to achieve virologic suppression. Multiple comorbidities and polypharmacy were not major drivers of virologic failure in our clinic cohort.
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